[ORGANIZATION]
daraxonrasib
Featured in 11 tracked stories · first seen
Situations
FDA approves Rasonque; EMA recommends for pancreatic cancer
44 clusters · 321 sources · last updated
Latest: Pancreatic cancer: New research and treatment developments in Greece
On 26 August 2026, the U.S. Food and Drug Administration (FDA) granted expedited approval to daraxonrasib, marketed as Rasonque, for treating adults with metastatic pancreatic ductal adenocarcinoma (PDAC). Developed by R
Also covered in
-
FDA approves daraxonrasib for metastatic pancreatic cancer
[HEALTH] · 4 sources ·